Cyclerion Therapeutics, Inc. (CYCN)
CYCN moved a median of 0.00% 30 minutes after news, and +1.98% by the close. How CYCN actually reacts to news — the realized, point-in-time move the market made, measured across 120 labeled events over the last three years with zero look-ahead.
CYCN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 30% | 76 |
| 30-min | 0.00% | 43% | 87 |
| 60-min | 0.00% | 48% | 95 |
| to close | +1.98% | 62% | 101 |
| Middle 50% of CYCN reactions | -1.91% to +2.25% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 120 |
Half of all Cyclerion Therapeutics, Inc. news events land between -1.91% and +2.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CYCN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CYCN's baseline. Nothing else.
Recent CYCN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Korsana Biosciences, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Cyclerion Therapeutics, For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +2.19% | -2.68% | |
| Form 8-K Cyclerion Therapeutics, For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | +4.53% | |
| Form 10-Q Cyclerion Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +1.43% | |
| Form EFFECT Cyclerion Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +3.95% | +2.64% | |
| Form S-4/A Cyclerion Therapeutics, | SEC filing · Form S-4 | SEC EDGAR | +0.00% | -0.82% | |
| Form S-4/A Cyclerion Therapeutics, | SEC filing · Form S-4 | SEC EDGAR | -0.78% | -0.39% | |
| Form S-4/A Cyclerion Therapeutics, | SEC filing · Form S-4 | SEC EDGAR | +6.76% | +4.39% | |
| Form 10-Q Cyclerion Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.46% | +1.62% | |
| Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | -0.61% | |
| Form 10-K/A Cyclerion Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.22% | +0.61% | |
| Form S-4 Cyclerion Therapeutics, | SEC filing · Form S-4 | SEC EDGAR | +1.03% | +3.09% | |
| Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.99% | +4.29% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSE - NSA), Urgent.ly, Inc. (OTC Markets - ULYX), UniFirst Corporation (NYSE - UNF) | Press release | GlobeNewswire | +1.32% | -4.42% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSE - NSA), Urgent.ly, Inc. (OTC Markets - ULYX), UniFirst Corporation (NYSE - UNF) | Press release | GlobeNewswire | +0.00% | +4.41% | |
| CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -1.01% | +24.49% | |
| Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement | Press release | Business Wire | +6.88% | +15.58% | |
| Form 8-K Cyclerion Therapeutics, For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -1.01% | +24.49% | |
| Form 10-K Cyclerion Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | +6.16% | |
| Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board | Press release | GlobeNewswire | -1.60% | -0.80% | |
| Form 8-K Cyclerion Therapeutics, For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | -1.60% | -0.80% | |
| Form 8-K Cyclerion Therapeutics, For: Jan 03 | SEC filing · Form 8-K | SEC EDGAR | -5.76% | -10.14% | |
| Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression | Press release | GlobeNewswire | -5.76% | -10.14% | |
| Form 8-K Cyclerion Therapeutics, For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -1.92% | |
| Form 10-K/A Cyclerion Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.50% | — | |
| Form 10-Q Cyclerion Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.50% | — | |
| Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company | Press release | GlobeNewswire | -4.79% | -8.45% | |
| Form 8-K Cyclerion Therapeutics, For: Sep 19 | SEC filing · Form 8-K | SEC EDGAR | -4.79% | -8.45% | |
| Form 10-Q Cyclerion Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.89% | -11.48% | |
| Form 8-K Cyclerion Therapeutics, For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | — | -8.38% | |
| Form EFFECT Cyclerion Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.56% | +4.83% | |
| Form 8-K Cyclerion Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -4.17% | -5.18% | |
| Form 10-Q Cyclerion Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.48% | +12.83% | |
| Form S-3 Cyclerion Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -1.48% | +12.83% | |
| Form DEF 14A Cyclerion Therapeutics, For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +4.86% | |
| Form DEFA14A Cyclerion Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +4.86% | |
| Form 8-K Cyclerion Therapeutics, For: Mar 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.54% | |
| Form 10-K Cyclerion Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.56% | -7.99% | |
| Form EFFECT Cyclerion Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.24% | -8.46% | |
| Form S-3 Cyclerion Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -0.16% | +5.66% | |
| Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth | Press release | GlobeNewswire | -2.87% | -6.02% | |
| Form 8-K Cyclerion Therapeutics, For: Dec 13 | SEC filing · Form 8-K | SEC EDGAR | -2.87% | -6.02% | |
| Form 10-Q Cyclerion Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.70% | +45.76% | |
| Form 10-Q Cyclerion Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +4.07% | |
| Form 8-K Cyclerion Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | — | +4.07% | |
| Regina Graul, Ph.D., Promoted to Chief Executive Officer | Press release | GlobeNewswire | — | +4.07% | |
| Form 8-K Cyclerion Therapeutics, For: Jun 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.75% | |
| Form 10-Q Cyclerion Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.43% | |
| Form DEF 14A Cyclerion Therapeutics, For: Jun 14 | SEC filing · Form DEF | SEC EDGAR | — | -7.52% | |
| Form DEFA14A Cyclerion Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | — | -7.52% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CYCN section they belong to.
Where else CYCN is measured.
CYCN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cyclerion Therapeutics, Inc.'s median reaction calculated?
Every labeled CYCN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 120 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of CYCN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CYCN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.